Recent estimates from 2024 and 2025 suggest that roughly 20% to 40% of people with advanced pancreatic cancer will experience a clotting event at some point during the course of their illness. This makes clotting disorders one of the most frequent complications associated with the disease.
The Khorana Risk Score
To determine which cancer patients face the highest likelihood of developing blood clots, clinicians often rely on a predictive tool known as the Khorana Risk Score. This model assesses several factors, including the type of cancer involved, platelet levels, hemoglobin concentration, and body mass index.
Each cancer type is assigned a baseline score based on its known risk of causing clotting problems. Pancreatic cancer automatically receives two points, placing patients directly into the high-risk category even before other risk factors are taken into account.
Prognostic Significance
For individuals with pancreatic cancer, blood clots are not merely a complication of the disease—they may also provide insight into how severe the cancer is. Research connected to the COMPASS trial in 2025 suggests that the early appearance of clots may be linked to particularly aggressive tumor subtypes.
When venous thromboembolism occurs within the first three months after diagnosis, it is often associated with tumors that have biological characteristics promoting faster growth and poorer survival outcomes. Because of this connection, doctors view sudden or unexplained leg swelling as a possible warning sign that the disease may progress more aggressively.
Protein Deficiencies and Systemic Edema
Not all swelling associated with pancreatic disease is caused by blood clots. In certain cases, swelling may appear in both legs due to a condition called systemic edema, which occurs when the body’s fluid balance becomes disrupted, according to the Mayo Clinic.
Albumin, a protein produced by the liver, plays a key role in keeping fluid contained within the blood vessels. When albumin levels drop too low, fluid begins to leak out of the vessels and accumulate in surrounding tissues, resulting in swelling.
Pancreatic tumors can interfere with this process because they may block the release of important digestive enzymes. Without these enzymes, the body struggles to properly absorb proteins from food. Over time, this can lead to a condition known as hypoalbuminemia, particularly in more advanced stages of the disease. In some cases, the tumor may also affect liver function or trigger widespread inflammation in the body, both of which can further reduce albumin levels.
This type of swelling commonly appears as pitting edema, which is usually most noticeable around the ankles and feet. A simple way to check for pitting edema is by gently pressing a finger into the swollen area—if a temporary indentation remains, it may indicate this condition. Unlike swelling caused by DVT, which typically affects only one leg, systemic edema usually develops gradually and tends to involve both legs.
Diagnostic Pathways: When Swelling Leads to Discovery
In some cases, swelling in the legs may be the earliest sign that leads to the discovery of pancreatic cancer. Because of this possibility, medical guidelines—such as those released by ESMO in 2025—recommend careful medical evaluation when leg swelling appears without a clear explanation. This recommendation is particularly important for individuals over the age of 50 or those with additional risk factors, including a history of smoking or unexplained weight loss.
The diagnostic process for possible pancreatic disease usually begins with initial testing. Doctors often start with a blood test that measures D-dimer levels, proteins that appear when the body is breaking down a blood clot. Research published by Seitz and colleagues in 2024 showed that elevated D-dimer levels can indicate the presence of a clot, although the test alone cannot confirm a diagnosis.
NEXT PAGE
